Journal Scan

Tolerability good, activity poor with cabazitaxel in adrenocortical carcinoma

Posted on

Despite having a manageable toxicity profile, cabazitaxel activity was poor active as second/third-line treatment in patients with metastatic adrenocortical carcinoma (ACC), according to the result of a phase II study.

These results do not support further evaluation of cabazitaxel in this setting, the authors concluded.

In this single-center study, 25 patients with disease progression to a cisplatin-containing regimen plus mitotane, plus/minus a further chemotherapy line were administered cabazitaxel intravenously at 25 mg/m2 on day 1 of a 21-day cycle, for a maximum of 6 cycles. The primary endpoint was a disease control rate after 4 months.

After 4 months of treatment, a disease control rate was achieved by 24% of patients. No patients attained a disease response, 36% had stable disease, and 64% had progressive disease. The median progression-free survival 1.5 months (range 0.3-7 months) and the median overall survival was 6 months (range 1-22.2 months.

Grade 3 toxicity, including nausea and anemia, was developed in 12% of patients, and cabazitaxel was considered well-tolerated.

Laganà M, Grisanti S, Ambrosini R, et al. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ESMO Open. 2022 Mar 7;7(2):100422. doi: 10.1016/j.esmoop.2022.100422. Epub ahead of print. PMID: 35272132.